

Genetic Signatures IPO closes oversubscribed

Sydney, Australia 24 March 2015: Genetic Signatures Ltd announced today that it has successfully closed its Initial Public Offering at the maximum raising of AUD7.5 million. The Company’s shares, which are to be issued at \$A0.40 per share, are anticipated to be listed on the ASX on 31 March 2015, under the ASX stock code, “GSS”.

Genetic Signatures’ CEO Dr John Melki said: “We are delighted to have achieved the maximum raise which reflects confidence in the company and its products. The proceeds of the IPO will be applied to accelerating the Company’s product development pipeline and to increasing new business development via the continued commercial rollout of our products in Australia and the EU as well as entry into the US market.”

Genetic Signatures’ diagnostic kits quickly and accurately screen patient samples for a wide array of pathogens that are most commonly associated with medical conditions such as gastroenteritis and respiratory infections.

“The ability to screen quickly and accurately for a wide array of infectious diseases (or pathogens) is a critical requirement for hospitals and pathology laboratories globally and is the first step in infection control. Genetic Signatures’ products have been developed to be platform agnostic, thereby maximising the addressable market by reducing the need for capital expenditure by customers.” said Dr. Melki

For further information, visit our website (www.geneticsignatures.com) or contact us as below:

Company	Media and Investor Relations
<p>John Melki Chief Executive Officer john@geneticsignatures.com T: +61 2 9870 7580</p> <p>Robert Birrell Chief Financial Officer rob@geneticsignatures.com T: +61 2 9870 7580</p>	<p>Peter Taylor Investor Relations peter@nwrcommunications.com.au T: +61 412 036 231</p>

About Genetic Signatures: Genetic Signatures is a specialist molecular diagnostics (MDx) company focused on the development and commercialisation of its proprietary platform technology, *3Base™*. Founded in 2001 by the late Dr Geoffrey Grigg, the former Chief of Molecular Biology at CSIRO, Genetic Signatures has released a suite of real-time Polymerase Chain Reaction (PCR) based products for the routine detection of infectious diseases under the *EasyScreen™* brand.

Molecular diagnostics is a modern technique increasingly used by hospitals and pathology laboratories to detect specific sequences of the genome, the DNA or RNA that define an organism.

Genetic Signatures' proprietary MDx 3Base™ platform technology provides high-volume hospital and pathology laboratories the ability to screen for a wide array of infectious pathogens, with a high degree of specificity, in a rapid throughput (time-to-result) environment.

Genetic Signatures' current target markets are major hospital and pathology laboratories undertaking infectious disease screening. As the spread of infectious diseases around the world continues to grow, the Company plans to launch additional products for the detection of pathogens associated with MRSA, sexual health infections, tuberculosis and meningitis.